## **CERTIFICATE OF MAILING**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS,

P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON <u>December 20, 2004</u>

Name of Person Mailing the Document

Attorney Docket No.: P30693C4X1C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al. December 20, 2004

Serial No.: 09/922,067 Group Art Unit No.: 1652

Filed: 03 August 2001 Examiner: Manjunath N. Rao

For: Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of the Same in Diagnosis and Therapy

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents Mail Stop: Sequence Alexandria, Va 22313-1450

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
- (X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (g) does not include new matter.
- (X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (h) does not include new matter or go beyond the disclosure in the international application as filed.
- (X) I hereby state that the amendments, made in accordance with 37 CFR §1.825 (a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages 19-21. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

Respectfully submitted,

Attorney for Applicants Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968 Facsimile (610) 270-5090